PDRN and exosomes turn up in the same places: on clinic menus as skin boosters, in post-laser recovery serums, and increasingly in the same bottle. They are often described with the same words, "regenerative", "repair", "cell signalling", but they are different kinds of thing. This page sets them side by side and counts their trial records the same way, as of 26 October 2026. Each has its own page on this site with more depth: PDRN and exosomes in skincare.
What each one is
| PDRN | Exosomes | |
|---|---|---|
| What it is | Fragments of DNA, purified | Membrane-wrapped vesicles released by cells, carrying proteins, lipids and RNA |
| Usual source in aesthetics | Salmon or trout sperm; newer plant and bacterial versions | Human adipose (fat) stem cells, platelets, plants (rose, Centella), bacteria |
| One molecule or a mixture? | One class of molecule, varying in fragment length | A cell product; contents depend on the source cell and the process |
| Size | Tens of thousands of daltons and up | Whole nanometre-scale particles, not single molecules |
| How it is said to work | Binds the adenosine A2A receptor; supplies building blocks for cells | Delivers signalling proteins and RNA from the source cell |
The last row is the source of most of the confusion. PDRN's proposed mechanism is one receptor and one class of molecule, so it can be tested in a fairly defined way. "Exosomes" names a delivery package rather than its contents: two exosome products from different cells can carry very different cargo, which means a result from one does not transfer to another. What skincare labels actually declare under the word is counted on our exosomes page; most name no human exosome at all.
The trials, counted the same way
To compare like with like, we ran one search pattern for both on 26 October 2026: the ingredient terms joined with skin, facial, wrinkle, scar or rejuvenation in the title or abstract, then the randomized-controlled-trial filter.
| PDRN or polynucleotides | Exosomes or extracellular vesicles | |
|---|---|---|
| Records | 214 | 3,082 |
| Tagged randomized controlled trials | 10 | 11 |
| Tagged retracted | 2 (PDRN terms only) | 5 (exosome with skin) |
The exosome literature is fifteen times larger, but nearly all of it is laboratory and animal work; the randomized-trial counts are about the same. These numbers differ from the ones on each ingredient's own page because those pages used narrower searches on earlier dates; the method here is the same for both columns.
What the 21 randomized trials tested, read by title and abstract:
- PDRN and polynucleotides (10): almost all are injections. Polynucleotide fillers compared with hyaluronic-acid fillers around the eyes and in nasolabial folds, a polynucleotide booster against polycaprolactone, acne-scar injections, scar-prevention injections after thyroid surgery, a skin-graft pilot from 2001, an injection-pain study, and one dental trial (injections after wisdom-tooth extraction) that the skin terms caught.
- Exosomes (11): almost all are applied straight after a procedure or to a wound. Human fat-stem-cell exosomes after fractional CO2 laser for acne scars (25 people, split-face) and after microneedling for ageing (28 people, split-face), the same against platelet-rich plasma, rose-stem-cell exosomes after needling radiofrequency (6 people), autologous platelet exosomes, surgical scars, a purified exosome product on skin-graft donor sites (7 people, phase 1b), and a few the search caught that are not exosome skincare at all, including an oral probiotic study that measured bacterial vesicles in urine.
Neither column holds a vehicle-controlled trial of a serum on intact skin, which is the format most shoppers are buying.
No head-to-head trial
None of those 21 trials compares PDRN with exosomes. The nearest is a 2026 Baghdad trial in 100 people with atrophic acne scars (Helmi et al., Postępy Dermatologii i Alergologii), which applied a polynucleotide and "exosome-mimetic nanovesicles" together after fractional CO2 laser and compared the pair with laser alone. The combination did better on scar scores (47.3% versus 35.9% reduction), with less post-laser darkening (10% versus 24%) and less prolonged redness (14% versus 30%). That says the combination beat laser alone in one trial. It says nothing about which of the two did the work, and the vesicles were described as exosome-mimetic, not cell-derived exosomes.
The search trap: two different "exosomes"
Joining the two terms directly in PubMed returns 50 records, which looks like a small literature on combining them. It is mostly not. In molecular biology "exosome" also names an older, unrelated thing, an RNA-cutting enzyme complex inside cells, and "polynucleotide" appears in enzyme names such as polynucleotide phosphorylase. Read by title, the bulk of the 50 are about RNA processing in bacteria, archaea and yeast. Only a handful, including the Baghdad trial, a 2026 laboratory study that packed trout PDRN inside exosomes and several aesthetic reviews, concern skin. The same kind of word collision inflated the peptide hair serum count on this site; it is why every count here is read record by record.
What regulators say
- Exosomes: FDA's public safety notification of 6 December 2019 states that there are currently no FDA-approved exosome products and that exosomes used to treat diseases or conditions are regulated as drugs and biological products. Skincare that names exosomes is sold as cosmetic.
- PDRN: when this site searched FDA's 510(k) and premarket-approval databases on 24 September 2026, there was no cleared or approved PDRN or polynucleotide injectable; the one approved polydeoxyribonucleotide, defibrotide, is a liver medicine with no skin use. Topical PDRN is a cosmetic ingredient. The detail is on our PDRN page; why a Korean or European authorisation is not a US one is set out in the skin boosters overview.
How this compares with peptides
Both are often sold as alternatives to peptides. They are far larger than any cosmetic peptide, which is the opposite of an advantage for a serum on intact skin, and their trial records sit mostly in clinics rather than at the bathroom shelf. The peptide comparison, molecule size and trial counts side by side, is on our PDRN vs peptides page.
What can fairly be said
PDRN is a defined molecule with a single proposed mechanism and about ten small randomized trials, nearly all by injection. Exosomes are a cell product whose contents vary by source, with a vast laboratory literature and about ten small randomized trials, nearly all after a procedure or on a wound. Neither has been compared with the other, neither has been shown to work from a serum on intact skin, and neither is an FDA-approved treatment. Anyone weighing them as clinic treatments should ask what exactly is in the vial, where it came from and what it is approved for in that country, and take the answer to a dermatologist.
Sources
Opened 26 October 2026: PubMed searches (polydeoxyribonucleotide[tiab] OR PDRN[tiab] OR polynucleotide*[tiab]) AND (skin[tiab] OR facial[tiab] OR wrinkle*[tiab] OR scar*[tiab] OR rejuvenation[tiab]) (214; with randomized controlled trial[pt] 10, every title read); the same pattern for exosome*[tiab] OR "extracellular vesicle*"[tiab] (3,082; randomized 11, every title read); exosome terms with PDRN or polynucleotide terms (50, every title read); retraction filters (2 and 5); abstracts of PMIDs 42621380, 33073298, 37377400, 42155421, 41800727 and 40414798. FDA's 2019 exosome notification and the 24 September 2026 FDA database searches as recorded on this site's exosomes and PDRN pages. Corrections go to the contact page.